Morgan Stanley
NNNN

Morgan Stanley’s Anbio Biotechnology NNNN Stock Holding History

Morgan Stanley’s Portfolio NNNN Stock Details NNNN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$189K Buy
7,338
+7,310
+26,107% +$191K ﹤0.01% 5902
2025
Q4 		$842 Sell
28
-8,582
-100% -$236K ﹤0.01% 7407
2025
Q3 		$321K Buy
8,610
+8,210
+2,053% +$369K ﹤0.01% 5699
2025
Q2 		$12.7K Buy
+400
New +$3.83K ﹤0.01% 6785

Other funds holding NNNN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFS
Bare Financial Services Gap, Pennsylvania $436M AUM 20.22% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Morgan Stanley's NNNN Position: Q1 2026 in Review

Morgan Stanley increased its Anbio Biotechnology (NNNN) stake by 26,107% in Q1 2026, buying an estimated $191K and bringing the position to 7,338 shares worth $189K. The position accounts for ﹤0.01% of the portfolio, ranked #5902.

Morgan Stanley first reported a position in NNNN in Q2 2025 and has held it in 4 quarters since. The position peaked at $321K in Q3 2025. 8 funds tracked by Wall St. Rank hold NNNN as of Q1 2026.

  • Morgan Stanley held 7,338 shares of Anbio Biotechnology worth $189K as of Q1 2026.
  • Morgan Stanley bought 7,310 Anbio Biotechnology shares in Q1 2026, an estimated $191K.
  • Anbio Biotechnology made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5902 holding.
  • Morgan Stanley first reported a position in Anbio Biotechnology in Q2 2025 and has held it in 4 quarters since.
  • Morgan Stanley's Anbio Biotechnology position peaked at $321K in Q3 2025.
  • 8 funds tracked by Wall St. Rank held Anbio Biotechnology as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.